Red Yeast Rice for Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The extracts of red yeast rice (RYR) are currently the most effective cholesterol-lowering nutraceuticals. This activity is mainly due to monacolin K, a weak reversible inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, whose daily consumption causes a reduction in low-density lipoprotein (LDL)-cholesterol plasma levels up to 15% to 25% within 6 to 8 weeks. The decrease in LDL-cholesterol is accompanied by a proportional decrease in total and non-high-density lipoprotein cholesterol, plasma apolipoprotein B, and high-sensitivity C-reactive protein. Some trials suggest that RYR use is associated with improvement in endothelial function and arterial stiffness, whereas a long-term study supports its role in the prevention of cardiovascular events. Despite the statin-like mechanism of action, the risk related to 3 to 10 mg monacolin K taken per day is minimal (mild myalgia in previously severely statin-intolerant subjects). RYR could represent a therapeutic tool to support lifestyle improvement in managing mild to moderate hypercholesterolemia in low-risk patients, including those who cannot be treated with statins or other LDL-cholesterol-lowering therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Fernández-Friera, L., Fuster, V., López-Melgar, B., Oliva, B., García-Ruiz, J. M., Mendiguren, J., Bueno, H., Pocock, S., Ibáñez, B., Fernández-Ortiz, A., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.024 · Cited by 378
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O. A., Morgan, J. M., & Capuzzi, D. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.056 · Cited by 315
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284 · cited 1×
“However, polyunsaturated fatty acids have mainly a triglyceride (TG)-lowering effect (8), whereas the lipid-lowering efficacy of soy proteins seems to be”
BackgroundThe Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272 · cited 1×
“Despite the metabolism and the mechanism of action of monacolin K being the same of lovastatin, for reasons not yet fully elucidated, RYR seems to be well tolerated by previously statin-intolerant subjects, especially when monacolin K daily doses between 3 mg and 10 mg are used (52).”
BackgroundSelf-citationChiavaroli, L., Nishi, S. K., Khan, T. A., Braunstein, C. R., Glenn, A. J., Mejia, S. B., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Jenkins, D. J. A., et al. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.05.004 · Cited by 226 · cited 1×
“, purely plant based) and aggressive lifestyle changes have been associated with an LDL-C reduction up to 20% (5), but medium- to long-term adherence to such intensive lifestyle modification is generally poor, particularly in the primary prevention setting and challenging to implement in the medium to long term in our…”
BackgroundMarked Variability of Monacolin Levels in Commercial Red Yeast Rice Products: Buyer Beware!
Gordon, R. Y., Cooperman, T., Obermeyer, W., & Becker, D. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.382 · Cited by 184 · cited 1×
“However, in the market, RYR supplements were detected with levels of citrinin exceeding 114 mg per capsule, largely above the safety level (46).”
BackgroundJenkins, D. J., Kendall, C. W., Faulkner, D. A., Nguyen, T., Kemp, T., Marchie, A., Wong, J. M., de Souza, R., Emam, A., Vidgen, E., et al. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.83.3.582 · Cited by 184
Gerards, M. C., Terlou, R. J., Yu, H., Koks, C. H. W., & Gerdes, V. E. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.004 · Cited by 169
Halbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., Rader, D. J., & Becker, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.672 · Cited by 154
Poli, A., Barbagallo, C. M., Cicero, A. F. G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Bianchi, A., Canzone, G., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.05.015 · Cited by 134 · cited 1×
“Considering the very high prevalence of subjects with suboptimal LDL-C level in the general population (approximately 50%) (2), and the relatively small impact of lifestyle improvement on LDL-C levels (from 5% to 10%) (3), great attention has been recently given to single dietary components or natural compounds able t…”
BackgroundSelf-citationEFSA Panel on Dietetic Products, N. A. A. (. (2011) · EFSA Journal · doi:10.2903/j.efsa.2011.2304 · Cited by 84
Cicero, A. F. G., & Colletti, A. (2016) · Phytomedicine · doi:10.1016/j.phymed.2015.10.011 · Cited by 70
Self-citationMarazzi, G., Pelliccia, F., Campolongo, G., Quattrino, S., Cacciotti, L., Volterrani, M., Gaudio, C., & Rosano, G. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.023 · Cited by 48
Cicero, A. F. G., Fogacci, F., Rosticci, M., Parini, A., Giovannini, M., Veronesi, M., D’Addato, S., & Borghi, C. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0214-2 · Cited by 41 · cited 1×
“001) (22), in line with what was reported in previous smaller trials (23,24).”
ResultSelf-citationBecker, D. J., French, B., Morris, P. B., Silvent, E., & Gordon, R. Y. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.019 · Cited by 37
Cicero, A. F. G., Colletti, A., Fogacci, F., Bove, M., Rosticci, M., & Borghi, C. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0163-2 · Cited by 35
Self-citationBarrat, E., Zaïr, Y., Sirvent, P., Chauveau, P., Maudet, C., Housez, B., Derbord, E., Lescuyer, J.-F., Bard, J.-M., Cazaubiel, M., et al. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0486-2 · Cited by 31
Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190326 · Cited by 23 · cited 1×
“In statinintolerant subjects, adding RYR to the background therapy with ezetimibe increased the number reaching the desired LDL-C goal without increasing the adverse event rate (56,57).”
BackgroundSelf-citationRed Yeast Rice and Statin-Intolerant Patients
Cicero, A. F. G., Derosa, G., & Borghi, C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.337 · Cited by 17
Self-citationChiavaroli, L., Nishi, S., Khan, T. A., Braunstein, C. R., Glenn, A. J., Blanco Mejia, S., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Jenkins, D. J. A., et al. (2024) · doi:10.32920/26521333.v1
Cited by
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
“The decrease in LDL-C is accompanied by a proportional decrease in hs-CRP [76].”
BackgroundCicero, A. F. G., Fogacci, F., Stoian, A. P., Vrablik, M., Al Rasadi, K., Banach, M., Toth, P. P., & Rizzo, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00955-y · Cited by 110
Self-citationCicero, A. F. G., Kennedy, C., Knežević, T., Bove, M., Georges, C. M. G., Šatrauskienė, A., Toth, P. P., & Fogacci, F. (2021) · Nutrients · doi:10.3390/nu13020638 · Cited by 20
Self-citationThe Administration of Probiotics against Hypercholesterolemia: A Systematic Review
Sivamaruthi, B. S., Bharathi, M., Kesika, P., Suganthy, N., & Chaiyasut, C. (2021) · Applied Sciences · doi:10.3390/app11156913 · Cited by 20
“It improves the reduction of LDL-c associated with the improved function of the endothelium and arterial stiffness in CVD [22,23].”
Background
Metadata
- Authors
- Cicero, A. F. G., Fogacci, F., & Zambon, A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 77
- Issue
- 5
- Pages
- 620-628
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3126288346
- Cited by
- 99
- References
- 24
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.